3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Malignancies
1
Interventions
sitravatinib
1
Nivolumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Metastatic Non-Squamous Non-Small Cell Lung Cancer
×
sitravatinib
×
Clear all
NCT03906071
2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3
Completed
577 enrolled
22 charts